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Abstract
Background: The outcome of surgical intervention for hepatic metastases from gastrointestinal stromal tumours (GIST) is
still uncertain. This study evaluated the outcome of patients following aggressive surgical resection and Imatinib mesylate
therapy (IM). Patients and methods: This was a retrospective analysis of patients managed with hepatic metastases from
GISTover a 13-year period (January 1993 to December 2005). Results: Twelve patients were identified with a median age at
diagnosis of 62 (3278) years. The primary sites of GIST were stomach (n/5), jejunum (n/4), sigmoid (n/1),
peritoneum (n/1) and pancreas (n/1). Eleven patients underwent surgical resection with curative intent and one patient
had cytoreductive surgery. Following surgery with curative intent (n/11), the overall 2- and 5-year survival rates were both
91%, whereas the 2- and 5-year disease-free rates following primary hepatic resection were 30% and 10%, respectively. The
median disease-free period was 17 (372) months. Eight patients had recurrent disease and were managed with further
surgery (n/3), radiofrequency ablation (RFA) (n/2) and IM (n/8). Overall, there are four patients who are currently
disease-free: two patients following initial hepatic resection and two patients following further treatment for recurrent
disease. There was no significant association in clinicopathological characteristics between patients with recurrent disease
within 2 years and patients who were disease-free for 2 years or more. Overall morbidity was 50% (n/6), with one
postoperative death. The follow-up period was 43 (372) months. Conclusion: Surgical resection for hepatic GIST
metastases may improve survival in selected patients. Recurrent disease can be managed with surgery, RFA and IM.
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Introduction
Gastrointestinal stromal tumours (GIST) are the
most common mesenchymal tumours, and account
for 13% of all gastrointestinal malignancies [13].
These tumours demonstrate a broad spectrum of
biological behaviours, from indolent to rapidly pro-
gressive malignancies [4,5]. The liver is known to be a
common metastatic site for GISTand previous studies
have reported that 5572% of patients develop
hepatic metastasis following complete resection of
the primary tumour [68].
Previously described treatment modalities for he-
patic metastases from GIST include anthracycline-
and ifosfamide-based chemotherapy regimes [9,10],
hepatic arterial chemoembolization [11], surgical
resection [12,13] and hepatic transplantation [14].
However, high recurrence rates and poor survival
outcomes following hepatic transplantation have been
reported [14]. Previous studies have described radical
surgical resection, including hepatectomy, as a poten-
tial treatment modality for this clinical condition
[8,12].
More recently, the emergence of Imatinib mesylate
(STI571, GlivecTM), a tyrosine kinase inhibitor, has
been reported to induce a good response in cases of
GIST [15,16]. In the clinical setting, Imatinib mesy-
late has been successfully tested in patients with
metastatic and/or irresectable GIST [1719]. Cur-
rently, large randomized clinical trials are ongoing to
determine the effectiveness, safety, duration and
inclusion criteria of adjuvant Imatinib mesylate ther-
apy for patients with GIST.
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This study presents a retrospective review of the
management of patients with hepatic metastases from




Patients referred with hepatic metastasis from GIST
to the Hepatobiliary Unit, St James’s University
Hospital during the 13-year period, from January
1993 to December 2005 were identified using the
Hepatobiliary database. The medical records of these
patients were retrospectively reviewed for demogra-
phy, clinical presentation, radiological investigations,
treatment and clinical outcome (morbidity and mor-
tality). Preoperative radiological assessment included
thoracic, abdomen and pelvis CT and MRI of the
liver.
Surgery and follow-up
Surgical resection was classified as resection with
curative intent and palliative surgery. Surgical resec-
tion with intent to cure involved the complete resec-
tion of all tumours identified at operation, including
the primary tumour, hepatic metastases and other
intra-abdominal disease. Palliative surgery was de-
fined when resection of all tumours was not feasible.
Hepatic resection was performed using the Cavi-Pulse
Ultrasonic Surgical Aspirator (CUSA, Model 200T,
Valley Lab., Colorado, USA). Intraoperative ultra-
sound was performed to confirm the findings of
preoperative imaging and to assist in surgical plan-
ning.
Following initial postoperative review at 1 month,
all patients were examined in the outpatient clinic at
3, 6, 12, 18 and 24 months and annually thereafter. At
each clinic review at 3, 6, 12, 18 months, 2 years and
annually thereafter CT of chest, abdomen and pelvis
was performed. Liver MRI was used to define
suspicious lesions demonstrated on CT or in cases
of negative CT with recurrence of endocrine-related
symptoms.
Clinicopathological characteristics
Histopathological data of the primary tumour (loca-
tion), hepatic metastases (number and size of hepatic
metastases) and extrahepatic involvement were also
recorded and analysed. Patients were considered to
have incidental hepatic metastasis if the lesion was
discovered during a work-up for a different medical
problem. Synchronous hepatic metastasis was defined
as simultaneous identification of hepatic metastases
and primary GIST. Histopathological diagnosis of
GIST was based on the expression of CD117 antigen
(c-kit proto-oncogene protein product) on resected
specimens, which showed differentiation towards the
intestinal cells of Cajal on immunohistochemical
analysis [20].
Statistical analysis
Statistical analysis was performed using the Statistical
Package for the Social Sciences for WindowsTM
version 12.0 (SPSS Inc., Chicago, IL, USA), and
statistical significance was defined as pB/ 0.05. The
KaplanMeier method was used to assess the actuar-
ial survival and disease-free rate. Univariate analysis
(Mann-Whitney U test, x2 test and Fisher’s exact test)
was performed to assess for a difference in clinico-
pathological characteristics between patients with
recurrent disease within 2 years and patients that
were disease-free for 2 years or more.
Results
During the study period, 12 patients with hepatic
metastases from GIST were identified from the
database. The median age at diagnosis was 62 (32
78) years and the male to female ratio was 5:7.
The localization of the primary tumour was the
stomach (n/5), jejunum (n/4), sigmoid (n/1),
peritoneum (n/1) and pancreas (n/1). One patient
presented with synchronous primary GIST with
hepatic metastases and the remaining 11 patients
had metachronous hepatic metastases. The median
time interval between hepatic metastases and primary
tumour resection in these cases was 18 (5168)
months.
The most common symptom at presentation of
hepatic metastases was abdominal pain (n/7). One
patient presented with an abdominal mass and the
remaining four patients with hepatic metastases were
detected by surveillance imaging. All patients under-
went a complete imaging assessment, including ultra-
sound examination, abdominal and thoracic CT and
MRI of the liver. In addition, five patients had a bone
scan. Radical surgery with intent to cure was per-
formed in cases where metastatic hepatic tumours
were judged to be resectable on imaging studies.
One patient underwent a left lateral segmentectomy
as a cytoreductive procedure for the removal of
selected hepatic metastases that were resistant to
Imatinib mesylate therapy. Eleven patients underwent
surgical resection with intent to cure, which consisted
of right hepatic trisegmentectomy (n/5, three cases
having additional contralateral non-anatomical me-
tastectomies), right hepatectomy (n/1), right hemi-
hepatectomy with contralateral non-anatomical me-
tastectomies (n/1), left hepatectomy with contral-
ateral non-anatomical metastectomies (n/1) and
multiple non-anatomical metastectomies (n/3). In
addition, synchronous peritoneal tumours were iden-
tified in four patients, and combined resection of
these tumours was also performed (Table I).
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No. Age* (sex) Primary tumour Others
Time interval to hepatic







1 64 (F) Jejunum None 168 R hepatectomy None None None Disease-free (72)
2 33 (M) Stomach None 12 R trisegmentectomy None 27 IM Stable disease (60)
3 32 (F) Sigmoid None 10 R trisegmentectomy/ NAM None 17 IM and surgery Disease-free§ (43)
4 43 (F) Peritoneum None 36 R trisegmentectomy None 19 IM and surgery Stable disease (54)
5 78 (F) Stomach None 36 L hepatectomy / NAM Peritoneum resection 15 IM Stable disease (41)
6 61 (M) Pancreas None 24 NAM Peritoneum resection 17 IM and surgery Stable disease (54)
7 61 (M) Stomach None 12 R hemihepatectomy/NAM Peritoneum resection 5 IM and RFA Stable disease (37)
8 39 (F) Jejunum None 72 R trisegmentectomy/NAM Peritoneum and SB resection None None Disease-free (44)
9 67 (M) Jejunum None 5 NAM None 3 IM and RFA Stable disease (36)
10 45 (F) Stomach Liver 0 NAM Gastrectomy 6 IM Disease-free§ (29)
11 55 (M) Jejunum None 12 R trisegmentectomy/NAM None POD NA NA
12 69 (F) Stomach None 41 L lateral segmentectomy None NA NA Stable disease (3)
F, female; M, male; R, right; L, left; NAM, non-anatomical metastectomy/metastectomies; SB, small bowel; POD, postoperative death; IM, Imatinib mesylate; RFA, radiofrequency ablation; NA,
not applicable.
*Age refers to age at diagnosis at time of identification of hepatic metastases from GIST.
$Recurrence refers to disease recurrence following primary hepatic resection.
%Follow-up period is from the time of primary hepatic resection to last clinical follow-up.
§These patients are currently disease-free having following treatment of recurrent disease with further surgery, radiofrequency ablation and/or Imatinib mesylate (patient 3: disease-free for 13 months











Hepatic metastases specimens in all cases were
positive for CD117 (c-kit) expression on immunohis-
tochemical analysis. Multiple hepatic metastases were
present in 11 patients and 1 patient had a solitary
hepatic metastasis. Overall, the median number of
hepatic metastases was 5.5 (121) and the median
largest size of hepatic metastatic tumours from each
patient was 5 (0.714) cm. In five cases, there was
evidence of hepatic tumour on the resection margin.
The median hepatic resection margin to the tumour in
the remaining cases was 1 (0.57) mm. Statistical
analysis did not reveal a significant difference
in clinicopathological variables between patients
who were disease-free for less or more than 2 years
(Table II). There was also no association between the
involved resection margin and disease recurrence in
the remnant liver.
Recurrence within the remnant liver following
surgical resection occurred in eight patients, with
five of them having synchronous extrahepatic disease
 peritoneal (n/5) and lung (n/1). Three patients
with recurrent disease underwent further surgery
including multiple hepatic metastectomies, resection
of right lower lobe of lung for solitary metastasis and
excision of peritoneal GIST, respectively. Two pa-
tients were treated with open RFA for recurrent
hepatic metastases.
Ten patients in this series were treated with
Imatinib mesylate therapy, with four patients treated
preoperatively over a median period of 13.5 (355)
months. Three of the four patients proceeded to have
surgical resection with curative intent and the remain-
ing one patient had selected resection of hepatic
metastases that were resistant to Imatinib mesylate
therapy. Patients who were not managed with pre-
operative Imatinib mesylate therapy were not com-
menced on this therapy following primary hepatic
resection until detection of recurrence. Following the
detection of recurrent disease post-resection, eight
patients (including the two patients who had neoad-
juvant therapy) were commenced on Imatinib mesy-
late therapy. Currently, seven patients are receiving
Imatinib mesylate therapy for a median period of 36
(3155) months. Following a combination of treat-
ment modalities that included surgical resection, RFA
and/or Imatinib mesylate therapy for recurrent dis-
ease, there are two patients who are currently disease-
free (8 and 13 months, respectively) (Figure 1).
In patients that underwent surgery with intent to
cure, the overall 2- and 5-year actuarial survival rates
were both 91%, whereas the 2- and 5-year disease-free
rates following primary hepatic resection were 30%
and 10%, respectively. The median disease-free per-
iod was 17 (372) months (Figure 2). Overall, there
are four patients that are currently disease-free: two
patients following initial hepatic resection and two
patients following further treatment for recurrent
disease.
Overall morbidity was 50% (n/6). Four patients
(33.3%) had abdominal collection and three patients
(25%) developed a wound infection. There was one
postoperative death due to multi-organ failure and
sepsis secondary to small bowel perforation. The
overall follow-up period was 43 (372) months.
Discussion
There are significant prognostic implications in GIST
cases with hepatic metastasis [6]. Recent studies on
hepatic resection for metastases from GIST have
Table II. Clinical and pathological characteristics of patients with metastatic GIST in this study.
Disease-free period
Clinical and pathological characteristics
Less than 2 years
(n/7)
More than 2 years
(n/3) p value*
Demographics
Male:female ratio 3:4 1:2 1.000
Age at diagnosis: median (range) years 67 (3278) 39 (3364) 0.424
Time interval between hepatic metastasis and primary
resection: median (range) months
12 (036) 72 (12168) 0.108
Pathological analysis






Extrahepatic metastatic disease at presentation 3 1 1.000
Size of hepatic metastasis: median (range) cm 3.3 (0.714) 3.7 (212) 0.909
No. of hepatic metastases: median (range) 3 (27) 6 (121) 0.728
Resection margin: median (range) mm 1 (0.51.8) 1 (07) 0.726
*Statistical analysis was performed on 10 patients that had surgical resection of metastatic disease with curative intent (2 patients were
excluded from analysis: 1 patient with early postoperative death and 1 patient with cytoreductive surgery).
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shown an overall median survival time of 39
(3340) months following surgery [6,8,12,13,21,22]
(Table III). However, in some of these series, the
results included patients with sarcomas and leiomyo-
sarcomas. It is not unreasonable to assume that the
majority of such lesions would be reclassified as GIST
in current practice. Nevertheless, these results suggest
that surgical resection is a recognized treatment
modality for hepatic metastases from GIST and does
have a contributory effect on the overall survival rate.
In the present study, all patients except one are
currently alive, with a median follow-up period of
43 months.
Previous studies have reported high recurrence
rates following surgical resection for hepatic metas-
tases from GIST, i.e. median/71.5%, range/50
84% [8,12,13,21,22]. Some clinicians have advocated
the use of different treatment modalities to manage
recurrent disease following hepatic resection including
chemotherapy [13], hepatic arterial chemoemboliza-
tion [12,16], further resection of the remnant liver
[12,13] and peritoneal recurrence [6,8,23], RFA [13]
and Imatinib mesylate therapy [13,24,25]. Although
complete resection of GIST in the abdominal cavity
has been reported to improve the survival outcome
[6,8,23], extra-abdominal recurrences have a poor
prognosis [12]. In this study, the majority of cases had
disease recurrence within 2 years following surgical
resection. Eight patients with recurrent disease in the
remnant liver (including four with additional extra-
hepatic disease), were treated with further surgery,
RFA, Imatinib mesylate therapy or a combination of
12 patients with hepatic metastases from GIST
Neoadjuvant IM therapy (n = 4)
Postoperative death (n = 1)Recurrent disease (n = 8)
Treatment of recurrent disease
(surgical resection, RFA
and/or IM therapy, n = 8)
Stable disease (n = 7)





Disease-free (n = 4)
2
IM therapy (n = 1)
6
Figure 1. Management and clinical outcomes of patients with hepatic metastases from GIST in this study. GIST, gastrointestinal stromal
tumour; RFA, radiofrequency ablation; IM, Imatinib mesylate (STI571, GlivecTM).



















Figure 2. Disease-free rate in patients with hepatic metastases from
GIST in this study. /, disease-free patients.
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these modalities. This resulted in two patients with
recurrent disease being currently disease-free and the
remaining patients having stable disease. This in-
cluded a patient with lung metastasis who is alive at 54
months following initial hepatic resection. The cur-
rent data suggest that further surgical resections for
recurrent hepatic disease and peritoneal recurrence
should be attempted when feasible and a combination
with other treatment modalities such as RFA and
Imatinib mesylate therapy is thought to be safe and
improves clinical outcome.
Due to the difference in its natural history and high
recurrence rates, some authors suggest that hepatic
metastases from GIST should not be managed in a
similar fashion to hepatic colorectal metastasis [13].
Hepatic metastases from GIST could indicate that
systemic disease is already present and surgical resec-
tion is merely palliative. Nevertheless, results from the
present study suggest that recurrent disease managed
with further surgery, RFA, Imatinib mesylate therapy
or a combination of these modalities does improve
prognosis.
Various studies have attempted to determine prog-
nostic factors for hepatic metastases from GIST. The
disease-free interval between primary surgery and
recurrence, or the duration between hepatic resection
and recurrence, has been shown to be a significant
prognostic predictor of survival [8,13]. DeMatteo et
al. showed that a time interval from the primary
tumour to the development of hepatic metastasis/2
years was a significant predictor of survival following
hepatectomy [8]. Nunobe and co-workers found that
the only significant prognostic factor following hepa-
tectomy was a 5-year period to the development of
recurrence [13]. Other investigators have reported
similar findings [22]. Another study revealed that
primary GIST size and mitotic rate were the most
useful parameters to predict malignant potential [25].
Patel and Benjamin demonstrated that prognostic
factors associated with improved survival following
recurrent disease were disease-free intervals/18
months, recurrence limited to the peritoneal cavity
or liver and complete resection of metastatic disease
[26]. However, the status of the microscopic resection
margin did not alter the survival rate [8]. Other
reports have also demonstrated a trend towards an
improved survival rate when comparing isolated liver
metastasis to all other abdominal recurrences
[6,8,27]. Nevertheless, this series did not identify
any significant prognostic factors from clinical and
pathological characteristics of hepatic metastases from
GIST. This may be due to the small sample size in this
study.
The underlying mechanism of the development of
GIST is thought to be due to the gain-of-function
mutation of the c-kit gene, resulting in activation of its
product, KIT receptor tyrosine kinase [28]. Imatinib
mesylate is a selective inhibitor of tyrosine kinase
activity of c-kit and clinical trials have reported good
efficacy and improved survival outcomes in patients
with metastatic GIST [16,17,19,2931]. The clinical
response to Imatinib mesylate therapy is determined
by the type of c-kit mutation [15,16,3032]. In this
series, all patients treated with Imatinib mesylate
therapy demonstrated c-kit expression. Three patients
treated preoperatively with Imatinib mesylate therapy
had a significant response and proceeded to have
hepatic resection with intent to cure. This may
suggest that neoadjuvant Imatinib mesylate therapy
could further expand the indications for surgical
resection. All patients under adjuvant Imatinib mesy-
late therapy complementing other treatment modal-
ities for recurrent disease now have stable disease or
are currently disease-free. The full potential of Im-
atinib mesylate therapy is yet to be elucidated and
trials are in progress to determine its role in the
management of this disease.
Conclusion
Surgical resection with curative intent for hepatic
metastases from GIST should be considered when
feasible, as it may improve survival outcomes in
selected patients. Recurrence of disease can be
managed with further surgery, RFA, Imatinib mesy-
late therapy or a combination of these treatment
modalities.











Ng et al. [6] 19571987 (1992) Houston, USA 5 33 Not recorded
Chen et al. [21] 19841995 (1998) Baltimore, USA 6 39 3 (50%)
Lang et al. [22] 19831996 (2000) Hannover, Germany 18 40 9 (60%)
DeMatteo et al. [8] 19821998 (2000) New York, USA 56 39 47 (84%)
Shima et al. [12] 19892001 (2003) Kochi, Japan 10 39 7 (70%)
Nunobe et al. [13] 19842003 (2005) Tokyo, Japan 18 36 14 (77%)
Present series 1993 2005 Leeds, UK 12 43 8 (73%)
*Recurrence represents disease recurrence in patients following primary hepatic resection with curative intent.
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